Senior Investigator Profile

First NamePeter
Award StatusTerm 2
Current PostProfessor of Clinical Pharmacology
DepartmentNational Heart & Lung Institute
Telephone0207 594 1100
InstitutionImperial College London
NHS TrustImperial College Healthcare NHS Trust
Region NameLondon
Primary Research FieldInternal Medicine
Secondary Research FieldCardiology & Cardiovascular Disease
BiographyPeter Sever is Professor of Clinical Pharmacology and Therapeutics at Imperial College London and Honorary Consultant Physician at the Imperial College Healthcare NHS Trust. He is co-Director of the International Centre for Circulatory Health and Head of the Disease Prevention Section of the National Heart and Lung Institute, Imperial College London. In 2009, was appointed as a Senior Investigator of the National Institute for Health Research and reappointed in 2014. After graduating from the University of Cambridge, Professor Sever completed his training at St Mary’s Hospital Medical School in London. He became an Honorary Consultant Physician and Senior Lecturer in Medicine at St Mary’s Hospital in 1976. In 1980, he was appointed Professor of Clinical Pharmacology and Therapeutics at St Mary’s Hospital Medical School, which was subsequently incorporated into the Imperial College School of Medicine. Professor Sever is Joint Editor-in-Chief of the Journal of the Renin-Angiotensin-Aldosterone System. Professor Sever is a past President of the British Hypertension Society and the European Council for Blood Pressure and Cardiovascular Research and past Chairman of the Fellowships Committee of the British Heart Foundation. He is also a Fellow of the European Society of Cardiology. In 2010, he was presented with the AstaZeneca Award from the International Society for Hypertension for his contribution to the clinical pharmacology and therapy of arterial hypertension. He was elected an Honorary Fellow of Trinity Hall Cambridge in 2011. Professor Sever’s research interests include the pathophysiology of vascular disease, the evaluation of antihypertensive drug therapy and the impact of multiple risk factor intervention for the prevention of cardiovascular disease.


<< Search SI Directory